Continuous Glucose Monitoring Devices Market (2026-2032)
The Global Continuous Glucose Monitoring Devices Market was valued at approximately USD 14.05 billion in 2025 and is projected to reach around USD 30.7 billion by 2032, expanding at a CAGR of approximately 11.8% during 2026-2032.
Quick Enquiry
Continuous Glucose Monitoring Devices Market: Recurring Sensor Sales, Type 2 Diabetes Expansion, and Wider Pharmacy Access Accelerate Global Growth
The Global Continuous Glucose Monitoring Devices Market was valued at approximately USD 14.05 billion in 2025 and is projected to reach around USD 30.7 billion by 2032, expanding at a CAGR of approximately 11.8% during 2026–2032, according to MarketsandStats.
Market growth is being driven by rising sensor demand, wider CGM use among people with Type 2 diabetes, broader reimbursement, and easier pharmacy access. The addressable patient base remains large, with approximately 37–40 million people living with diabetes in the United States and more than 500 million globally. Type 2 diabetes accounts for around 90–95% of U.S. cases and more than 95% of diabetes cases worldwide, creating a substantial population for broader CGM adoption.
Abbott and Dexcom remain the leading companies. Abbott generated approximately USD 7.6 billion in global CGM sales in 2025, while Dexcom reported around USD 4.66 billion. Medtronic remains important through integrated CGM and automated insulin-delivery systems, while Senseonics competes through long-duration implantable CGM. Chinese companies including SiBionics, MicroTech Medical, Yuwell, and Sinocare are increasing competition in lower-cost and digitally distributed CGM systems.
The large diabetes burden and expanding use of CGM beyond intensive insulin management are widening the market across both developed and underpenetrated countries. Rising replacement sensor demand, stronger reimbursement coverage, and growing access through pharmacy and digital channels are expected to remain the main contributors to market expansion through 2032.
Why Sensor Replacement Is Becoming the Largest Revenue Pool in CGM
Sensors account for the largest share of CGM revenue because patients need regular replacements to maintain continuous glucose monitoring. As CGM use expands across Type 1 and Type 2 diabetes care, repeat sensor demand continues to rise, making sensors the main source of recurring revenue in the market.
Abbott serves more than 7 million FreeStyle Libre users globally, while Dexcom reported approximately 3.5 million active customers at the end of 2025, excluding Stelo. This broad use of CGM across diabetes care supports steady replacement sensor demand and reinforces both companies’ strong positions in reimbursement coverage, distribution, and ongoing product development.
Sensors are estimated to represent approximately 78% of overall CGM market revenue in 2025, significantly ahead of receivers, transmitters, and software-related components. As CGM penetration increases, sensor sales volume is expected to remain the main driver of absolute market expansion through 2032.
Real-Time CGM Takes a Larger Share of Spending
Real-time CGM holds the largest share of the market, supported by products such as Dexcom G6 and G7, newer FreeStyle Libre systems, and Medtronic Guardian and Simplera. Demand is rising as healthcare providers increasingly favor continuous glucose data, automatic alerts, and easier integration with diabetes-management platforms.
Intermittently scanned CGM remains important in cost-sensitive markets, although newer products are gradually narrowing the gap with real-time systems by offering more automated monitoring and alerts.
Implantable CGM remains a smaller segment, led by Senseonics' Eversense 365. Its longer wear duration offers an alternative for patients seeking fewer sensor replacements and more continuous long-term monitoring.
Type 2 Diabetes Opens the Next Large CGM Revenue Pool
CGM adoption was initially concentrated among people with Type 1 diabetes who require intensive insulin management. The larger growth opportunity is now moving toward Type 2 diabetes.
Insulin-treated Type 2 patients are increasingly receiving CGM coverage because continuous glucose data can improve treatment adjustment and reduce dependence on repeated finger-stick testing. Manufacturers are also expanding toward selected non-insulin-treated Type 2 populations.
Type 2 diabetes is becoming an increasingly important source of CGM demand as monitoring expands beyond intensive insulin therapy into broader diabetes management. Wider use among Type 2 patients is increasing the number of people requiring continuous glucose data and supporting higher recurring sensor demand.
For Abbott and Dexcom, this expands the addressable patient population beyond the traditional Type 1 diabetes base and creates additional growth opportunities through broader routine glucose monitoring.
United States CGM Market: Nearly 156 Million Sensor Sales Support the World's Largest Revenue Pool
The United States Continuous Glucose Monitoring Devices Market was valued at approximately USD 7.0 billion in 2025, representing close to half of global CGM revenue. Annual sensor sales reached approximately 156 million units, supported by an active installed base of roughly 5.2 million CGM users.
The U.S. combines high sensor consumption with relatively high annual spending per patient, making it the world's most valuable CGM market.
Dexcom generated approximately USD 3.33 billion in U.S. revenue during 2025, while Abbott's U.S. CGM business is estimated at around USD 3.2 billion. Together, the two companies account for the overwhelming majority of U.S. market revenue.
Dexcom supplied approximately 83 million sensors in the U.S. during 2025, while Abbott supplied around 62 million units. Medtronic contributed approximately 10 million sensors, primarily through users connected to its broader insulin-pump and automated insulin-delivery ecosystem.
Sensor replacement remains the main source of recurring CGM revenue in the U.S. as patients continue using the technology for ongoing diabetes management. Rising adoption among Type 2 diabetes patients is expanding this demand beyond the traditional Type 1 population.
Broader Medicare coverage, private insurance support, pharmacy benefit access, and wider prescribing are making CGM available to more patients who previously relied on conventional glucose monitoring.
Pharmacies and retail channels now account for most U.S. CGM sales, while durable medical equipment suppliers remain important for insulin-dependent patients and pump-integrated systems. Direct-to-patient fulfillment also supports continued access to replacement sensors.
High reimbursement coverage, more than 150 million annual sensor purchases, broad pharmacy access, and rising CGM use among people with Type 2 diabetes continue to make the United States the largest and most commercially important CGM market.
China CGM Market: Nearly 38 Million Sensor Sales Create a High-Growth Volume Opportunity
The China Continuous Glucose Monitoring Devices Market was valued at approximately USD 600 million in 2025, with annual sensor sales reaching nearly 38 million units. Lower device prices and strong domestic competition have made China a high-volume CGM market, even though revenue remains well below the U.S.
Abbott leads the market with approximately USD 280 million in CGM revenue and around 18 million sensors sold during 2025. Domestic companies are also gaining a meaningful position. SiBionics accounted for approximately USD 85 million and 5.9 million sensors, followed by Yuwell with USD 34 million and 2.6 million units, MicroTech Medical with USD 30 million and 2.1 million units, and Sinocare with USD 25 million and around 2 million sensors. Other domestic suppliers contributed close to 3 million additional units.
The growing presence of Chinese manufacturers is increasing price competition and widening access to continuous glucose monitoring. Their stronger position in lower-priced sensors is helping China build sensor volumes faster than revenue, making the country an increasingly important CGM market for large-scale diabetes monitoring.
E-Commerce Is Reshaping China's CGM Distribution
Retail and e-commerce are the largest CGM sales channels in China, accounting for approximately USD 310 million in 2025 revenue and more than 20 million sensor units. Medical-device distributors contribute around USD 160 million, followed by direct-to-patient channels at approximately USD 76 million and hospitals and clinics at around USD 55 million.
The strong role of retail and digital channels is improving access to CGM products, particularly for domestic brands. Competition among lower-priced systems is also widening adoption beyond premium users and supporting higher sensor volumes.
China's large diabetes population and still-low CGM penetration leave substantial room for further adoption, making the country increasingly important to global sensor demand.
Japan CGM Market: 11.8 Million Annual Sensors Support a High-Value Specialist Market
The Japan Continuous Glucose Monitoring Devices Market was valued at approximately USD 480 million in 2025, with annual sensor sales reaching around 11.8 million units. Abbott leads the market with approximately USD 300 million in CGM revenue and around 7 million sensor units sold during the year.
Dexcom contributed approximately USD 80 million, representing around 2.2 million sensors, while Medtronic generated approximately USD 100 million from about 2.6 million sensor units.
Demand in Japan is supported by specialist diabetes care, physician prescribing, reimbursement, and wider use of CGM alongside insulin therapy. Abbott benefits from broad standalone CGM adoption, while Medtronic has a stronger position among patients using pump-integrated and automated insulin-delivery systems. Dexcom remains active in real-time glucose monitoring, particularly among patients requiring continuous and higher-frequency glucose data.
Distribution Remains More Healthcare-Led
Retail and pharmacy-linked channels generated approximately USD 195 million of Japan's CGM revenue in 2025, followed by medical-device distributors at around USD 144 million. Hospitals and clinics contributed approximately USD 78 million, while direct sales accounted for around USD 63 million.
The comparatively strong role of healthcare providers reflects Japan's clinically managed diabetes-care system, where physicians and specialist centers remain important to CGM adoption. Continued use among insulin-treated patients, broader adoption in Type 2 diabetes care, and increasing integration with automated insulin-delivery systems are expected to support further sensor demand.
Pharmacy and Retail Channels Gain Commercial Importance
Retail pharmacy and e-commerce channels account for approximately 61% of CGM revenue, making them the largest sales channel. DME suppliers and medical-device distributors contribute around 24%, followed by direct-to-patient channels at approximately 11% and hospitals and clinics at around 4–5%.
Wider pharmacy access is improving CGM availability and supporting regular sensor replacement, while e-commerce is becoming especially important in China, where domestic manufacturers use digital platforms to reach a larger self-paying patient base. Sales channel reach is therefore becoming an important factor in market share expansion.
Competitive Leadership Remains Concentrated Despite Growing Asian Competition
Abbott remains the largest global CGM manufacturer, supported by FreeStyle Libre, more than 7 million users worldwide, and approximately USD 7.6 billion in CGM sales during 2025. Dexcom follows with approximately USD 4.66 billion in global revenue, supported by strong U.S. demand and broad use of its real-time CGM systems.
Medtronic holds an important position through its integration of CGM with insulin pumps and automated insulin-delivery systems, while Senseonics serves a smaller segment through implantable CGM technology.
Competition is also increasing from Chinese companies such as SiBionics, MicroTech Medical, Yuwell, and Sinocare. Their lower-priced sensors and strong digital distribution are expanding adoption in self-pay markets and increasing competitive pressure across Asia.
Analyst Commentary
Continuous Glucose Monitoring development is increasingly focused on longer sensor wear, broader access beyond insulin-intensive diabetes care, tighter integration with automated insulin-delivery systems, and more advanced software-based glucose interpretation. CGMs are also moving gradually into broader health and wellness use, while updates such as Dexcom’s Trends tab are making glucose data easier to review by bringing key patterns and patient information into a single dashboard. At the same time, lower-cost sensors and wider pharmacy and digital distribution are increasing competition for Type 2 diabetes patients and self-pay users.